title: A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet-B light in patients with hematologic malignancy.
abstract: BACKGROUND
  Irradiation of platelet concentrates (PCs) with ultraviolet-B (UVB) light inactivates the contaminating white cells and might be an alternative to filtration for the prevention of alloimmunization to HLA antigens and subsequent refractoriness to further platelet transfusions in multiply transfused patients with bone marrow failure.
  
  
  METHODS
  Patients with hematologic malignancy, mainly acute myeloid leukemia, were prospectively assigned in a random manner to receive either UVB-irradiated or control, nonirradiated PCs. All patients were given red cells that were white cell reduced by filtration. Transfusion efficacy and alloimmunization were assessed by means of corrected count increments, requirement for red cells and PCs, and measurement of lymphocyte-reactive antibodies.
  
  
  RESULTS
  UVB-irradiated PCs had a clinical efficacy similar to controls as judged by corrected count increments at 1 to 6 and 12 to 24 hours and by the median requirement for red cell and platelet transfusions. Alloimmunization determined by measurements of lymphocyte-reactive antibodies using both conventional and antiglobulin-augmented lymphocytotoxicity techniques was not abolished in recipients of UVB-irradiated PCs (4/30, 13%) but was less than that in controls (5/20, 25%; p = NS). The mean number of platelet transfusion episodes prior to the occurrence of alloimmunization was greater in the control group (27 vs. 10; p = 0.017).
  
  
  CONCLUSIONS
  In this trial, UVB irradiation did not diminish the clinical efficacy of platelet transfusions. There was a small but nonsignificant reduction alloimmunization, but no difference in refractoriness of the two groups was observed. Larger prospective randomized studies are required to confirm these findings and to compare UVB irradiation with white cell reduction.
authors.affiliation: Regional Transfusion Centre, Bristol, UK.
authors.forename: E L
authors.initials: EL
authors.lastname: Blundell
authors.forename: D H
authors.initials: DH
authors.lastname: Pamphilon
authors.forename: I D
authors.initials: ID
authors.lastname: Fraser
authors.forename: J E
authors.initials: JE
authors.lastname: Menitove
authors.forename: T J
authors.initials: TJ
authors.lastname: Greenwalt
authors.forename: E L
authors.initials: EL
authors.lastname: Snyder
authors.forename: A J
authors.initials: AJ
authors.lastname: Repucci
authors.forename: S L
authors.initials: SL
authors.lastname: Hedberg
authors.forename: J K
authors.initials: JK
authors.lastname: Anderson
authors.forename: D H
authors.initials: DH
authors.lastname: Buchholz
authors.forename: L R
authors.initials: LR
authors.lastname: Kagen
authors.forename: R H
authors.initials: RH
authors.lastname: Aster
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001792:Blood Platelets / Q000276:immunology / Q000528:radiation effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007114:Immunization; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008223:Lymphoma / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D017713:Platelet Transfusion / Q000009:adverse effects; D011446:Prospective Studies; D014466:Ultraviolet Rays